VNS Therapy has been proven to decrease or sometimes eliminate seizures and may improve quality of life in many patients whose seizures do not respond to medications alone. In addition,

VNS Therapy has not been reported to cause any of the devastating side effects that are commonly associated with AEDs, and may allow some people with epilepsy to reduce the number or dose of the antiepileptic medications they take.

VNS Therapy with the Cyberonics NCP System was approved in 1997 for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with medically refractory partial onset seizures. In addition, the NCP System is currently approved for epilepsy in all the member countries of the European Union, Canada, and Australia. VNS with the Cyberonics NCP System is also approved for sale in the European Union and in Canada as a depression treatment in patients with treatment-resistant or treatment-intolerant major depressive episodes including unipolar depression and bipolar disorder (manic depression).

'"/>

Contact: Meaghan Atkinson
212-601-8438
Porter Novelli
18-Apr-2002